Can Ozempic prevent cancer? The headlines are moving much faster than the science

Recent studies have linked GLP-1 medications to lower rates of some cancers, but association is not proof. The evidence is encouraging, although it remains far too early to call Ozempic a cancer-prevention drug. The idea is powerful enough to travel quickly: a weekly injection already used for diabetes and weight loss might also reduce the risk of cancer.

Recent studies have given that possibility some support. Large reviews of medical records have found lower rates of several cancers among people taking GLP-1 medicines, the group that includes Ozempic, Wegovy and other drugs. The findings have generated headlines suggesting that these medications may do far more than control blood sugar or help people lose weight.

The problem is not that the research is meaningless. The problem is that an association found in health records is not the same as proof that a drug prevents cancer. Physician and clinical epidemiologist Ziyad Al-Aly recently examined this difference in an analysis published by The Conversation. His central warning was that public excitement is moving ahead of what the evidence can currently support.

For patients in St. Maarten and elsewhere, Ozempic is not approved as a cancer-prevention drug, and the available evidence does not justify taking it for that purpose.

A promising pattern

A 2024 study examined the health records of more than 1.6 million people with type 2 diabetes. Those prescribed GLP-1 drugs had lower rates of 10 of 13 cancers associated with obesity when compared with patients using insulin.

The list included colorectal, pancreatic, liver, ovarian, endometrial, gallbladder and kidney cancers, along with multiple myeloma and meningioma. However, researchers found no decrease in cancer risk when GLP-1 users were compared with patients taking metformin.

Another study, published in 2025, compared more than 43,000 GLP-1 users with a similar number of nonusers who had overweight or obesity. The GLP-1 group had a 17 per cent lower overall rate of cancer, with clearer reductions reported for endometrial cancer, ovarian cancer and meningioma. Researchers also identified a possible increase in kidney cancer that requires further study.

Those are substantial findings, and they deserve attention. Obesity is associated with at least 13 cancers, partly through excess hormones, insulin resistance and chronic inflammation. A medication that produces weight loss and improves metabolic health could reasonably influence some of those risks. Still, reasonable is not the same as proven.

Who is being compared?

The most important detail in many medical studies is not simply what happened to people taking a drug. It is who they were compared with. In the 2024 study, GLP-1 users appeared to have lower cancer rates than people using insulin. The same clear advantage did not appear when they were compared with people taking metformin.

That changes how the result should be understood. Patients who require insulin may have more advanced diabetes, may have lived with the disease longer and may already face greater health risks. When a newer drug is compared with treatment used by a sicker group, the newer drug can appear more protective than it really is.

The difference may partly reflect the starting health of the two groups rather than a cancer-preventing effect from the medication. A similar problem arises with access. People able to obtain GLP-1 medicines may have better insurance, more regular medical care and greater access to screenings. They may also be more likely to receive early treatment for other conditions.

Researchers can adjust their calculations for many differences, but medical records cannot capture everything. The drug may receive credit for advantages that existed before the first injection.

Cancer also takes time

Cancer can develop over many years. That makes claims of prevention difficult to prove when patients have been followed for only a limited period. Some studies have reported lower cancer rates relatively soon after people started GLP-1 treatment. That speed should create caution.

A medicine that prevents cancers from forming would usually be expected to show its effect gradually. Tumours diagnosed shortly after treatment begins may have already been developing before the patient received the medication. When a benefit appears almost immediately, it may indicate that the groups were different from the beginning. It does not automatically mean the drug acted quickly against cancer.

What stronger studies show

Randomized trials provide a more reliable comparison because participants are assigned to treatment groups rather than prescribed a drug through ordinary medical care. Two major reviews of randomized trials published in 2025 found little evidence that GLP-1 drugs changed overall cancer risk.

One review included 50 trials and found no significant difference in overall cancer rates. A second examined 48 trials involving more than 94,000 participants and concluded that the medications probably have little or no effect on several obesity-related cancers.

Those findings do not prove that the medicines have no effect. Most of the trials were designed to study diabetes, weight loss or heart-related outcomes, not cancer. Follow-up was often too short and the number of cancer cases too small to settle the question. They do, however, show why confident headlines are premature. The strongest available trial evidence is much quieter than the observational findings.

What about earlier cancer concerns?

The discussion has shifted sharply. GLP-1 drugs were once widely discussed as a possible cancer risk, particularly for thyroid and pancreatic cancers. They are now being described in some headlines as possible protection.

The current Ozempic label carries a boxed warning because semaglutide caused thyroid C-cell tumours in rodents. It remains unknown whether the same risk applies to humans. The medication should not be used by people with a personal or family history of medullary thyroid carcinoma or the inherited condition known as Multiple Endocrine Neoplasia syndrome type 2.

The broader research has not established that GLP-1 medicines increase overall cancer risk. That is reassuring, but it is not the same as proving they prevent cancer. The correct conclusion sits between fear and hype.

The benefit may not come from the drug alone

Even if future research confirms lower rates of some cancers, another question will remain: what produced the reduction? The benefit could come from weight loss. It could result from improved blood sugar, lower insulin levels, reduced inflammation or changes in hormones. Researchers are also examining whether GLP-1 drugs have more direct effects on the immune system or certain tumours.

Different cancers have different causes. A medication could reduce the risk of one, have no effect on another and raise concern around a third. Cancer is not one illness receiving one simple verdict.

What patients should understand

People prescribed Ozempic or another GLP-1 medicine for an approved medical reason may find the early cancer findings encouraging. They should not start the drug solely because of claims that it prevents cancer, and they should not change or stop treatment without consulting their doctor.

Ozempic is approved for adults with type 2 diabetes, including certain heart and kidney-risk reductions. Cancer prevention and treatment are not among its approved uses. Established cancer-prevention measures remain important: avoiding tobacco, maintaining a healthy weight, remaining physically active, receiving recommended vaccines and completing appropriate screenings. A weekly injection does not replace those steps.

Research into GLP-1 medicines and cancer is worth following. The early signals could eventually lead to new prevention or treatment strategies, particularly for cancers associated with obesity. For now, the most accurate conclusion is less dramatic than the headline. GLP-1 drugs do not appear to raise overall cancer risk, but claims that they actively prevent cancer have not been proven.

The possibility is real. The verdict is not.

‍